Filtered By:
Source: Journal of Stroke and Cerebrovascular Diseases
Drug: Coumadin
This page shows you your search results in order of relevance. This is page number 3.
Order by Relevance | Date
Total 77 results found since Jan 2013.
Warfarin-Resistant Deep Vein Thrombosis during the Treatment of Acute Ischemic Stroke in Lung Adenocarcinoma
A 66-year-old man with acute ischemic stroke in the setting of lung adenocarcinoma developed acute-onset deep vein thrombosis (DVT) of the lower limbs after changing to warfarin from a heparin combination. The diagnosis of warfarin-resistant DVT was established based on the laboratory data and clinical evaluation. Heparin administration resulted in good control of thrombin regulation. Cancer patients are at high risk of venous thromboembolism, and the combination of these 2 conditions is known as Trousseau's syndrome.
Source: Journal of Stroke and Cerebrovascular Diseases - June 21, 2016 Category: Neurology Authors: Hiroyuki Naito, Shiro Aoki, Naoko Sumi, Kazuhide Ochi, Naohisa Hosomi, Hirofumi Maruyama, Masayasu Matsumoto Tags: Case Studies Source Type: research
Safety of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients Taking Warfarin with Subtherapeutic INR
Current guidelines allow the administration of intravenous recombinant tissue plasminogen activator (IV r-tPA) to warfarin-treated patients with acute ischemic stroke (AIS) who have an international normalized ratio (INR) of ≤1.7. However, concerns remain about the safety of using IV r-tPA in this situation due to a conceivable risk of symptomatic intracranial hemorrhage (sICH), lack of dedicated randomized controlled trials and the conflicts in the available data. We aimed to determine the risk of sICH in warfarin-tr eated patients with subtherapeutic INR who received IV r-tPA for AIS in our large volume comprehensive center.
Source: Journal of Stroke and Cerebrovascular Diseases - February 25, 2021 Category: Neurology Authors: Ashkan Mowla, Aurangzeb Memon, Seyed-Mostafa Razavi, Navdeep S. Lail, Caila B. Vaughn, Pegah Mohammadi, Robert N. Sawyer, Peyman Shirani Source Type: research
Risk Factors Control and Early Recurrent Cerebral Infarction in Patients with Symptomatic Intracranial Atherosclerotic Disease
Stroke caused by intracranial atherosclerotic disease (IAD) has the highest risk of early recurrence when compared to other stroke subtypes.1 Despite intensive medical management, the 1-year recurrence risk is as high as 15%.2,3 Uncontrolled risk factors may substantially influence stroke recurrence in symptomatic IAD. In the Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) trial, uncontrolled systolic blood pressure (SBP) (>140 mmHg) and elevated cholesterol (>200 mg/dL) were associated with increased recurrent stroke during follow-up.
Source: Journal of Stroke and Cerebrovascular Diseases - June 30, 2021 Category: Neurology Authors: Victor J. Del Brutto, David S. Liebeskind, Jose G. Romano, Iszet Campo-Bustillo, George Cotsonis, Azhar Nizam, Shyam Prabhakaran, MYRIAD investigators Source Type: research
Decompressive Surgery for Malignant Cerebral Venous Sinus Thrombosis: A Retrospective Case Series from Pakistan and Comparative Literature Review
Conclusions: Patients who received decompressive hemicraniectomy in Pakistan for CVST had excellent outcomes in all cases when intervention was performed with intact preoperative pupillary reflexes. Of the data reviewed, most reported (two-third) patients show the same prognosticators; however, one third show that even with nonreactive pupils complete recovery is possible.
Source: Journal of Stroke and Cerebrovascular Diseases - October 11, 2013 Category: Neurology Authors: Emmon Raza, Muhammad Shahzad Shamim, Muhammad Faisal Wadiwala, Bilal Ahmed, Ayeesha Kamran Kamal Tags: Original Articles Source Type: research
An Emergency Department Intervention to Increase Warfarin Use for Atrial Fibrillation
Conclusions: This practical stroke prevention quality improvement initiative was not associated with an increase in warfarin use among ED patients with AF.
Source: Journal of Stroke and Cerebrovascular Diseases - December 20, 2012 Category: Neurology Authors: Lesli E. Skolarus, Lewis B. Morgenstern, Phillip A. Scott, Lynda D. Lisabeth, Jillian B. Murphy, Erin M. Migda, Devin L. Brown Tags: Original Articles Source Type: research
Convexity Subarachnoid Hemorrhage Soon after Starting a Direct Oral Anticoagulant in 2 Patients with Acute Infarction
Convexity subarachnoid hemorrhage (cSAH) is typically due to head trauma, but various nontraumatic causes for cSAH are known also. Nontraumatic cSAH is most commonly associated with cerebral amyloid angiopathy (CAA) in the elderly or with reversible cerebral vasoconstriction syndrome in younger subjects,1 but cSAH rarely occurs subsequent to acute ischemic stroke.2 Direct oral anticoagulants (DOACs) are used to reduce the risk of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation and have favorable bleeding profiles as compared with warfarin,3,4 but here we describe 2 cSAH patients who ...
Source: Journal of Stroke and Cerebrovascular Diseases - August 13, 2020 Category: Neurology Authors: Yoichiro Sugita, Yoichiro Nishida, Satoru Ishibashi, Takanori Yokota Tags: Case Report Source Type: research
Current Advances in Endovascular Treatment of Intracranial Atherosclerotic Disease and Future Prospective
Intracranial atherosclerotic disease (ICAD) is an important cause of large vessel disease leading to acute ischemic stroke (AIS). Currently, medical management such as risk factor control, antiplatelet therapy, and lifestyle changes are considered the first-line of treatment to prevent transient ischemic attack (TIA) or AIS.1 The results of the Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) trial2 demonstrated that symptomatic ICAD is a high-risk cause of recurrent stroke and highlighted the need for better treatment strategies, leading to consideration for both better medical management and the possibility of a...
Source: Journal of Stroke and Cerebrovascular Diseases - December 22, 2020 Category: Neurology Authors: Mostafa Jafari, Thanh N. Nguyen, Santiago Ortega-Gutierrez, Muhammad Shazam Hussain, Ameer E. Hassan, Asad Ikram, Javed Khader Eliyas, Gustavo J. Rodriguez, Afshin A. Divani Tags: Review Article Source Type: research
Net Clinical Benefit of Rivaroxaban versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation: A Subgroup Analysis of J-ROCKET AF
Conclusion: Analysis of the NCB supports that rivaroxaban therapy provides clinical benefit for Japanese patients with AF.
Source: Journal of Stroke and Cerebrovascular Diseases - November 4, 2013 Category: Neurology Authors: Shinichiro Uchiyama, Masatsugu Hori, Masayasu Matsumoto, Norio Tanahashi, Shin-ichi Momomura, Shinya Goto, Tohru Izumi, Yukihiro Koretsune, Mariko Kajikawa, Masaharu Kato, Hitoshi Ueda, Kazuma Iekushi, Satoshi Yamanaka, Masahiro Tajiri, J-ROCKET AF Study Tags: Original Articles Source Type: research
Incidence, Mortality, and Risk Factors for Oral Anticoagulant–associated Intracranial Hemorrhage in Patients with Atrial Fibrillation
Warfarin, a vitamin K epoxide reductase inhibitor, is the oral anticoagulant most commonly used to reduce the risk of stroke in patients with atrial fibrillation (AF). Warfarin has proved to be efficacious for this purpose in multiple clinical trials. However, warfarin use is laborious and associated with an increased risk of intracranial hemorrhage (ICH). Various factors increase the risk of warfarin-related ICH, including older age, intensity of anticoagulation, hypertension, and history of cerebrovascular disease.
Source: Journal of Stroke and Cerebrovascular Diseases - October 29, 2014 Category: Neurology Authors: Rebbeca Grysiewicz, Philip B. Gorelick Tags: Review Article Source Type: research
Embolic Stroke during Apixaban Therapy for Left Atrial Appendage Thrombus
Left atrial appendage (LAA) thrombus is associated with atrial fibrillation (AF) and is a powerful predictor of cardiogenic thromboembolism. Warfarin is an established anticoagulant therapy for patients with LAA thrombus to prevent thromboembolic complications. Apixaban is superior to warfarin in the prevention of thromboembolic complications in patients with AF, and there are case reports showing apixaban-associated resolution of LAA thrombus; however, the efficacy and safety of apixaban for the treatment of LAA thrombus remains unproven.
Source: Journal of Stroke and Cerebrovascular Diseases - January 22, 2015 Category: Neurology Authors: Masaki Ohyagi, Kazuha Nakamura, Mutsufusa Watanabe, Hiroto Fujigasaki Tags: Case Report Source Type: research
Effects of Pretreatment with Warfarin or Rivaroxaban on Neurovascular Unit Dissociation after Tissue Plasminogen Activator Thrombolysis in Ischemic Rat Brain
In this study, we assessed the risks and benefits of pre-treatment with warfarin or rivaroxaban after tissue-type plasminogen activator (tPA) thrombolysis in ischemic rat brain.
Source: Journal of Stroke and Cerebrovascular Diseases - May 23, 2016 Category: Neurology Authors: Jingwei Shang, Toru Yamashita, Syoichiro Kono, Ryuta Morihara, Yumiko Nakano, Yusuke Fukui, Xianghong Li, Nozomi Hishikawa, Yasuyuki Ohta, Koji Abe Source Type: research
The Sex, Age, Medical History, Treatment, Tobacco Use, Race Risk (SAMe TT2R2) Score Predicts Warfarin Control in a Singaporean Population
Warfarin reduces stroke risk in atrial fibrillation (AF) patients but requires ongoing monitoring. Time in therapeutic range (TTR) is used as a measure of warfarin control, with a TTR less than 60% associated with adverse patient outcomes. The Sex, Age, Medical history, Treatment, Tobacco use, Race (SAMe-TT2R2) score has been identified as a model able to predict warfarin control, but this has been tested in mainly Caucasian populations. Therefore, the aim of this study was to determine the ability of the SAMe-TT2R2 score to predict warfarin control in a Singaporean population consisting of Chinese, Malay, and Indian race.
Source: Journal of Stroke and Cerebrovascular Diseases - September 22, 2016 Category: Neurology Authors: Nijole Bernaitis, Chi Keong Ching, Liping Chen, Jin Shing Hon, Siew Chong Teo, Andrew K. Davey, Shailendra Anoopkumar-Dukie Source Type: research
Anticoagulant's character: Hemorrhagic vs. ischemic stroke
【Background】Anticoagulants have switched from warfarin to direct oral anticoagulants (DOACs) because they are believed to have more effects and lower hemorrhagic risks. However, intracranial hemorrhage really occurs in patients treated with DOACs.
Source: Journal of Stroke and Cerebrovascular Diseases - March 18, 2017 Category: Neurology Authors: Tatsuya Koike, Takahisa Mori, Kazuhiro Yoshioka, Yuhei Tanno, Shigen Kasakura, Noriyoshi Nakai Source Type: research
